AD is a growing market with an impressive pipeline of new products from current and future players in the field.

Amgen has shared positive results from a late-stage study of its immunotherapy Imdelltra (tarlatamab-dlle) in small cell lung cancer (SCLC). The global DeLLphi-304 trial has been comparing the drug ...

With the recent developments in the atopic dermatitis (AD) market, the field is becoming more competitive as novel therapies are soon anticipated to enter the market. This evolution may benefit AD ...

The facility is set to produce DS for biopharmaceuticals, leveraging the company's protein engineering and antibody ...

Amgen today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who progressed on or ...

Historical trends and future projections of the number of people with overweight and obesity suggest alarming parallel ...

Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and onl ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Approximately 60% to 85% of patients who develop ...

The company's latest PC processor, Kirin X90, has received China's Level 2 national certification... Save my User ID and Password Some subscribers prefer to save their log-in information so they ...